-
Highlighted Tests
-
why choose ambry
Ambry places significant value on implementing new lab processes designed to increase quality, and advancing technology across the field with innovative approaches. Our ongoing participation in numerous research studies and collaborations is so that we can better assess clinical validity of gene-disease relationships. This is to ensure that the results healthcare providers receive are as accurate and informative as possible. That’s why we led the largest study of its kind (20,000 cases) guiding us on additional confirmatory testing when we saw specific well-defined thresholds, reducing the chance of delivering a false positive patient report or one that misses real mutations (Mu et al., November 2016). The more accurate the reports, the more insight healthcare providers will have to treat their patients.
Choose from one of our more frequently ordered tests listed below.
CancerNext®
When finding the answer is critical for guiding your patient’s healthcare, CancerNext is a comprehensive 34-gene panel that identifies inherited risks for at least 8 types of cancers, giving you more information to make better treatment and management decisions.
CustomNext-Cancer®
For patients with a complex personal or family history of cancer, CustomNext gives you the flexibility to choose which genes to analyze so you can accurately diagnose, treat, and manage your patient’s cancer risks.
BRCANext®
Management guidelines-based panel including 19 genes associated with hereditary breast and/or gynecologic cancers.
BRCANext-Expanded®
BRCANext-Expanded is a 21 gene panel associated with hereditary breast and/or gynecologic cancers.
ProstateNext®
Since hereditary prostate cancer is not well understood or often recognized, clinicians need clear results to guide treatment decisions. ProstateNext is a 14-gene panel which offers more precision to identify and manage hereditary prostate cancer.
ColoNext®
Patients with a suspicious personal or family history of colorectal cancer or polyps benefit from early detection and cancer prevention. Identify patients with an increased risk by using ColoNext, a 20-gene panel designed to provide more precise data to help guide personalized medical management recommendations such as earlier or more frequent colonoscopies.
BRCAPlus®
To understand your patient’s risk and minimize uncertain results, you need a genetic test designed specifically for patients with a high risk personal and/or family breast cancer history. BRCAPlus tests critical breast cancer genes with published guidelines for medical management, so you can help your patient make confident, personalized screening and prevention decisions.
-
-
Breast
-
For patients with a personal/family history of breast, ovarian, colorectal, uterine, and/or other cancers
-
Breast
For patients with a personal/family history of breast, ovarian, colorectal, uterine, and/or other cancers
Name TAT Genes CancerNext® 14-21 days 34
-
-
For patients with a personal/family history of breast cancer
-
Breast
For patients with a personal/family history of breast cancer
Name TAT Genes BRCANext® 14-21 days 19 BRCANext-Expanded® 14-21 days 21 BRCAPlus® 7-10 days 13
-
-
Single syndrome testing options
-
Breast
Single syndrome testing options
Name TAT Genes BRCA1/BRCA2 6-10 days 2
-
-
For patients with a personal/family history of breast, ovarian, colorectal, uterine, and/or other cancers
-
Gastrointestinal
-
For patients with a personal/family history of colorectal, uterine, breast, ovarian, and/or other cancers
-
Gastrointestinal
For patients with a personal/family history of colorectal, uterine, breast, ovarian, and/or other cancers
Name TAT Genes CancerNext® 14-21 days 34
-
-
For patients with a personal/family history of colorectal cancer and/or polyps
-
Gastrointestinal
For patients with a personal/family history of colorectal cancer and/or polyps
Name TAT Genes ColoNext® 14-21 days 20
-
-
For patients with a personal/family history of pancreatic cancer
-
Gastrointestinal
For patients with a personal/family history of pancreatic cancer
Name TAT Genes PancNext® 14-21 days 13 PancNext® plus Pancreatitis 14-21 days 19
-
-
Single syndrome testing options
-
Gastrointestinal
Single syndrome testing options
Name TAT Genes Lynch syndrome 14-21 days 5 Familial Adenomatous Polyposis 14-21 days 1 MUTYH-associated Polyposis 14-21 days 1
-
-
For patients with a personal/family history of colorectal, uterine, breast, ovarian, and/or other cancers
-
Gynecologic
-
For patients with a personal/family history of colorectal, uterine, breast, ovarian, and/or other cancers
-
Gynecologic
For patients with a personal/family history of colorectal, uterine, breast, ovarian, and/or other cancers
Name TAT Genes CancerNext® 14-21 days 34
-
-
For patients with a personal/family history of gynecologic cancer
-
Gynecologic
For patients with a personal/family history of gynecologic cancer
Name TAT Genes BRCANext® 14-21 days 19 BRCANext-Expanded® 14-21 days 21
-
-
Single syndrome testing options
-
Gynecologic
Single syndrome testing options
Name TAT Genes Lynch syndrome 14-21 days 5 BRCA1/BRCA2 6-10 days 2
-
-
For patients with a personal/family history of colorectal, uterine, breast, ovarian, and/or other cancers
-
Urologic
-
For patients with a personal/family history of colorectal, uterine, breast, ovarian, and/or other cancers
-
Urologic
For patients with a personal/family history of colorectal, uterine, breast, ovarian, and/or other cancers
Name TAT Genes CancerNext® 14-21 days 34
-
-
For patients with a personal/family history of prostate cancer
-
Urologic
For patients with a personal/family history of prostate cancer
Name TAT Genes ProstateNext® 14-21 days 14
-
-
For patients with a personal/family history of kidney cancer
-
Urologic
For patients with a personal/family history of kidney cancer
Name TAT Genes RenalNext® 14-21 days 20
-
-
For patients with a personal/family history of colorectal, uterine, breast, ovarian, and/or other cancers
-
Comprehensive
-
Comprehensive
Comprehensive Testing
Name TAT Genes CustomNext-Cancer® 14-21 days 91 CancerNext-Expanded® 14-21 days 71 CancerNext® 14-21 days 34
-
-
Other
-
Other
Other Hereditary Cancer Testing Options
Name TAT Genes BrainTumorNext® 14-21 days 29 PGLNext® 14-21 days 14 MelanomaNext® 14-21 days 9
-
-
Single Gene
-
Single Gene
Single gene testing options
Name TAT APC gene sequence and deletion/duplication analysis 14-21 days ATM gene sequence and deletion/duplication analysis 14-21 days BAP1 gene sequence and deletion/duplication analysis 14-21 days BRCA1/BRCA2 gene sequence and deletion/duplication analysis 6-10 days BMPR1A/SMAD4 gene sequence and deletion/duplication analysis 14-21 days CDH1 gene sequence and deletion/duplication analysis 14-21 days CDKN2A/CDK4 gene sequence and deletion/duplication analysis 14-21 days CHEK2 gene sequence and deletion/duplication analysis 14-21 days DICER1 gene sequence and deletion/duplication analysis 14-21 days EPCAM deletion/duplication analysis 7-14 days FH gene sequence and deletion/duplication analysis 14-21 days FLCN gene sequence and deletion/duplication analysis 14-21 days MEN1 gene sequence and deletion/duplication analysis 14-21 days MITF specific site analysis 7-14 days MLH1 gene sequence and deletion/duplication analysis 14-21 days MRE11A gene sequence and deletion/duplication analysis 14-21 days MSH2 gene sequence and deletion/duplication analysis, MSH2 inversion analysis, and EPCAM deletion/duplication analysis 14-21 days MSH6 gene sequence and deletion/duplication analysis 14-21 days MUTYH gene sequence and deletion/duplication analysis 14-21 days NF1 gene sequence and deletion/duplication analysis 14-21 days NF2 gene sequence and deletion/duplication 14-21 days PALB2 gene sequence and deletion/duplication analysis 14-21 days PMS2 gene sequence and deletion/duplication analysis 14-21 days PTCH1 gene sequence and deletion/duplication analysis 14-21 days PTEN gene sequence and deletion/duplication analysis 14-21 days RB1 gene sequence and deletion/duplication analysis 14-21 days RET gene sequence 14-21 days SMARCB1 gene sequence and deletion/duplication 14-21 days STK11 gene sequence and deletion/duplication analysis 14-21 days TP53 gene sequence and deletion/duplication analysis 14-21 days TSC1/TSC2 gene sequence and deletion/duplication analysis 14-21 days VHL gene sequence and deletion/duplication analysis 14-21 days
-